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Etiology matters – Genomic DNA 
Methylation Patterns in Three Rat 
Models of Acquired Epilepsy
Konrad J. Dębski1, Asla Pitkanen2, Noora Puhakka2, Anna M. Bot1, Ishant Khurana3, 
KN Harikrishnan3, Mark Ziemann3, Antony Kaspi3, Assam El-Osta3, Katarzyna Lukasiuk1,* & 
Katja Kobow4,*
This study tested the hypothesis that acquired epileptogenesis is accompanied by DNA methylation 
changes independent of etiology. We investigated DNA methylation and gene expression in the 
hippocampal CA3/dentate gyrus fields at 3 months following epileptogenic injury in three experimental 
models of epilepsy: focal amygdala stimulation, systemic pilocarpine injection, or lateral fluid-
percussion induced traumatic brain injury (TBI) in rats. In the models studies, DNA methylation and 
gene expression profiles distinguished controls from injured animals. We observed consistent increased 
methylation in gene bodies and hypomethylation at non-genic regions. We did not find a common 
methylation signature in all three different models and few regions common to any two models. 
Our data provide evidence that genome-wide alteration of DNA methylation signatures is a general 
pathomechanism associated with epileptogenesis and epilepsy in experimental animal models, but the 
broad pathophysiological differences between models (i.e. pilocarpine, amygdala stimulation, and post-
TBI) are reflected in distinct etiology-dependent DNA methylation patterns.
According to the WHO, 60 million individuals have epilepsy worldwide, and in 30% of patients, available treat-
ments are ineffective or cause life-compromising adverse events1,2. Identifying novel mechanisms that lead to the 
development of epilepsy (epileptogenesis) and its progression culminating in drug-refractory epilepsy is a major 
unmet medical need3–5. Recent evidence indicates a spectrum of dysfunctional epigenetic mechanisms that occur 
during epileptogenesis, including acute changes in DNA methylation, histone modifications, and microRNA 
expression6. Kobow et al. demonstrated epilepsy associated changes in methylation of the reelin promoter is asso-
ciated with granule cell dispersion in epileptic subjects7. Epigenetic changes have since been reported by several 
laboratories in different epilepsy models (for review, see6,8,9). These studies have suggested that in epilepsies trig-
gered by traumatic brain injury (TBI) or status epilepticus (SE), epigenetic changes are associated with inherited 
and acquired etiological factors and complex reorganization of neuronal and glial networks during epileptogene-
sis. Because the etiologies of epilepsy vary greatly, a critical question is whether there are general mechanisms that 
could be targeted to design treatments for epileptogenesis after different types of brain insults.
We have hypothesized that epileptogenesis is accompanied by genomic methylation changes. To assess 
whether hippocampal DNA methylation patterns are common between different epilepsy models, we investi-
gated three animal models of acquired epilepsy: focal SE (electrical stimulation of the amygdala), systemic SE 
(pilocarpine), and TBI in rats. The models share some qualitative similarities in hippocampal circuitry reorgani-
zation believed to lead to the development of epilepsy such as synaptic, axonal and dendritic plasticity, suggesting 
common molecular mechanisms of epileptogenesis.
In the present study, genomic DNA methylation patterns distinguished controls from injured animals point-
ing at a general pathomechanism associated with epileptogenesis. Nevertheless, the broad pathophysiological 
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differences between models (i.e. pilocarpine, amygdala stimulation, and post-TBI) were reflected in distinct 
etiology-dependent epigenetic and gene expression signatures.
Results
We hypothesized that epileptogenesis is accompanied by specific gene expression changes mediated by DNA 
methylation. To investigate this we compared DNA methylation in three experimental models of epilepsy. We 
used methyl-capture and massive parallel sequencing (Methyl-Seq) of hippocampal tissue obtained from rats at 3 
months following focal amygdala stimulation, systemic pilocarpine injection, or lateral fluid-percussion-induced 
TBI with corresponding sham-treated controls. Genome-wide methylation patterns in the pilocarpine model 
have been previously described in detail10. Here we reanalyzed the publicly available data (NCBI Gene Expression 
Omnibus accession number GSE50080) and integrated these with our results. To analyze the biological relevance 
of methylation changes, we examined changes in gene expression using mRNA sequencing in the same samples 
(mRNA-Seq). We focused on integrative analysis of datasets obtained from the three models, which had distinct 
pathology in the hippocampus (Fig. 1).
Genomic DNA methylation signatures distinguish models of acquired epilepsy from controls. 
Pairwise comparisons of global DNA methylation was performed for models of epilepsy (sham versus injury) 
separately to allow to concentrate on injury/epilepsy related alterations and omit those related to e.g. strain, 
living conditions or handling procedures in different labs. We observed strong differences in methylation pat-
terns between control and injured animals in all three epilepsy models (Fig. 2a–c). Unsupervised clustering of 
differentially methylated regions (p < 0.01 between control and epileptic animals) in the amygdala stimulation 
(Fig. 2a), TBI (Fig. 2b), and pilocarpine (Fig. 2c) model suggests DNA methylation distinguishes injured epilepto-
genic hippocampal tissue in each model. We identified 2741 hypomethylated and 1866 hypermethylated regions 
in epileptic tissue from the amygdala stimulation model compared to controls; 1121 hypomethylated and 1452 
hypermethylated regions in pilocarpine treated epileptic animals over healthy controls; and 2171 hypomethylated 
and 2344 hypermethylated regions in the TBI model as compared to controls.
We conclude alterations to genomic DNA methylation provide a general pathomechanism associated with 
epileptogenesis.
DNA methylation events commonly shared between epilepsy models. To investigate common-
alities between animal models, we intersected differentially methylated regions from all three datasets. Regions 
overlapping by at least one base pair and with methylation changes occurring in the same direction were defined 
as common. The heatmap presented in Fig. 2d shows results from unsupervised clustering (using z-scores cal-
culated separately for each model, p < 0.01) of those regions with changes in methylation common to two mod-
els. Clusters distinguish all control animals from injuries, regardless of their genetic background and etiology. 
However, it has to be noted that the majority of observed alterations in genomic DNA methylation in each model 
were related to the initial precipitating injury and subsequent epileptogenic process.
We further mapped differentially methylated regions to the rat genome (RN5) using Circos, as shown in 
Fig. 2e. Increased (yellow) and decreased (blue) probability of methylation change was assigned to each chromo-
some (as -log10 of p-value). In all models methylation events were distributed throughout the genome, excluding 
chromosome X. Some differences between models could be observed. In the focal amygdala stimulation model, 
Figure 1. Pattern of neurodegeneration in three models of acquired epilepsy. Nissl-stained sections 
presenting dentate gyrus of animals from amygdala stimulation (a2), pilocarpine (b2) and TBI (c2) model and 
respective controls (a1,b1,c1). Arrows indicate neuronal loss.
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Figure 2. Differentially methylated regions and their distribution in three models of epilepsy.  
(a–c) - Unsupervised hierarchical cluster analysis of differential methylation in (a) amygdala stimulation, (b) TBI,  
and (c) pilocarpine models. Hypermethylation – yellow, hypomethylation – blue, green – control, magenta - SE/
TBI. (d) - Heatmap summarizing overlapping regions with consistent change in DNA methylation in at least 2 of 
3 models of epilepsy (p < 0.01). Hypermethylation – yellow, hypomethylation – blue, green – control, magenta - 
SE/TBI. (e) - Rat genome ideogram summarizing the probability of increased (yellow) or decreased (blue) DNA 
methylation in injured vs. control animals in three animal epilepsy models. Outer ring represents chromosomes. 
Inner rings indicate location of methylation events in each model (amygdala stimulation - light blue, TBI - 
light green, pilocarpine - light red, hypermethylation – yellow, hypomethylation – blue). Distance from black 
line in the middle of each ring represents increasing probability of methylation change (presented as -log10 of 
p-value). Arrowheads indicate areas in chromosomes 6 and 15 that lacked increased methylation in the amygdala 
stimulation model. (f) - Rat genome ideogram summarizing DNA methylation changes common for pairs of 
models (inner gray rings). Outer ring represents chromosomes. Red bars - common increased methylation events, 
blue bars - common decreased methylation events. (g) - Venn diagram presenting differentially methylated DNA 
regions detected in each model of epilepsy and regions overlapping between models with change in methylation  
to the same direction. (h–j) - Genomic distribution of DNA methylation changes in (h) amygdala stimulation,  
(i) TBI, and (j) pilocarpine models. Frequency of observed methylation changes compared with non-differentially 
methylated regions (p < 0.01), with upper and lower 95% confidence intervals for different genomic features. 
Magenta - increased methylation, green - decreased methylation, O/E - observed/expected ratio, CpG - CpG 
islands, SNP - single nucleotide polymorphism, TSS - transcriptional start site, UTR - untranslated region.  
(k) - Ratio of increased to decreased methylation events across genomic features for each epilepsy model with 
upper and lower 95% confidence intervals. Blue, green and light red bars represent the focal amygdala stimulation, 
TBI, and systemic pilocarpine models, respectively. *p < 0.05, **p < 0.01, ***p < 0.001 (two-sided Fisher’s exact test).
www.nature.com/scientificreports/
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some areas did not exhibit increased methylation, e.g. chromosome 6 and 15, in contrast to the systemic pilocar-
pine and TBI models (black arrowheads in Fig. 2e). More focused analysis identified only twenty-four differen-
tially methylated regions to be common to focal amygdala stimulation and TBI models, 20 were common to focal 
amygdala stimulation and systemic pilocarpine models, and 29 were common to TBI and systemic pilocarpine 
models (Fig. 2d,f,g). Two regions in promoters, 15 in gene bodies, and 10 in non-genic areas were common to the 
focal amygdala stimulation and TBI models. Four regions in promoters, 9 in gene bodies, and 11 non-genic areas 
were common to the focal amygdala stimulation and systemic pilocarpine models. Two regions in promoters, 16 
in gene bodies, and 16 in non-genic areas were common to the TBI and systemic pilocarpine models. No DNA 
methylation events were common to all three models. Few regions displayed methylation changes in the opposite 
direction: 9 between the amygdala stimulation and TBI; 8 between amygdala stimulation and systemic pilocar-
pine; and 15 between systemic pilocarpine and TBI.
We conclude that the localization of hypo- and hypermethylation is primarily model-specific.
Genomic distribution of DNA methylation in the three epilepsy models. To determine whether 
alterations in methylation status occur preferentially in specific genomic features, we compared the distribution of 
hypo- and hypermethylation events at CpG islands, single nucleotide polymorphisms (SNP), promoters (200 bp 
and 5 kb upstream of transcription start), transcription start sites (TSS), gene body (including 5′ and 3′ untrans-
lated regions), 5′ untranslated regions (5′ UTR), coding exons (protein coding part of exon), introns, 3′ UTR, 
and non-genic regions. Figure 2h–j show the mean frequency of methylation changes with upper and lower 95% 
confidence intervals for the described genomic features in all three models of acquired epilepsy. A preliminary 
analysis of the distribution of methylation changes in the pilocarpine-induced model of epilepsy was performed 
by Kobow et al.10. Here, we extended the list of evaluated genomic features.
We observe methylation changes at genomic features were predominantly model-specific. For example, 
in the focal amygdala stimulation model, hypermethylation events were frequently observed in CpG islands, 
SNPs, promoters (5 kb), gene bodies, coding exons, introns, and 3′ UTRs. In contrast, hypomethylation events 
occurred less frequently than expected in most genomic features, as shown by the negative odds ratios. Infact, 
non-genic regions exhibited a different profile in this model, with an increased probability of hypomethylation 
and decreased probability of hypermethylation (Fig. 2h).
In the TBI model, hypermethylation was primarily observed in gene bodies, coding exons, introns, and 
3′ UTRs and rarely affected CpG islands, promoters (200 bp), TSS, and non-genic regions. Hypomethylation 
occurred more frequently in non-genic regions and less frequently in promoters (5 kb), gene bodies, coding 
exons, and introns (Fig. 2i).
Re-analysis of the pilocarpine epilepsy model10 verified increased DNA methylation in most genomic fea-
tures including 3′ and 5′ UTRs, promoter sequences (200bp and 5 kb), as well as SNPs (Fig. 2j). Next, we com-
pared altered methylation events at specific genomic features between models (Fig. 2k). We observed decreased 
hypermethylation in non-genic regions in the three models, suggesting an overlap. Hypermethylation was more 
frequent in SNPs, gene bodies, coding exons, introns, and 3′ UTRs in the three models. Interestingly, an increase 
in methylation frequency in CpG islands was found in the focal amygdala stimulation and systemic pilocarpine 
models only. In the focal amygdala stimulation model, increased methylation frequency was detected in 5′ UTRs 
and promoters (5 kb).
Gene expression patterns differentiate control from injury-induced epilepsy models. Pairwise 
comparisons of RNA-sequencing were performed for the amygdala stimulation model (Fig. 3a) which was similar 
to the pilocarpine model previously published by Kobow et al. (see Fig. 3 in Kobow et al.) and reanalyzed in this 
paper (Fig. 3c)10. In the TBI model samples were partially mixed. One out of five samples from injured animals 
was more similar in the expression pattern to control animals (Fig. 3b). Altogether we found 54 upregulated 
and 231 downregulated genes in the amygdala stimulation model, 140 upregulated and 28 downregulated genes 
following TBI, and 184 upregulated and 126 downregulated genes in the pilocarpine model. Lists of genes with 
altered expression are presented in the Supplementary Tables 1 and 2. In summary, RNA expression patterns can 
distinguish injured and control animals in all three models.
Gene expression changes common to the three epilepsy models. When samples from all three exper-
imental animal models were combined (z-score calculated separately for each model; genes with expression changes 
in the same direction for at least two models), unsupervised clustering of gene expression patterns separated most 
control from epileptic animals, although the separation was not complete (Fig. 3d). Some control samples (3 out of 
15) clustered with injured animals, and some of injured animals (2 out of 14) clustered with control animals.
To determine which expression changes were common to more than one experimental model, we compared lists 
of differentially expressed genes (cut-off p <  0.001) from all three datasets. Fourteen upregulated and no downregu-
lated genes were common to the amygdala stimulation and TBI models, 33 upregulated and 3 downregulated genes 
were common to the amygdala stimulation and pilocarpine models, and 27 upregulated and no downregulated genes 
were common to the TBI and pilocarpine models (Fig. 3e,f). Additionally, 7 upregulated genes were common to all 
three epilepsy models: Serping 1 [serpin peptidase inhibitor, clade G (C1 inhibitor), member 1], Emp3 (epithelial 
membrane protein 3), S100a6 (S100 calcium binding protein A6), Msn (moesin), Cd44 (CD44 molecule), Aspg 
(asparaginase), and Gpnmb [glycoprotein (transmembrane) nmb] (Fig. 3e). We conclude that the gene expression 
pattern is primarily model-specific, although some genes behave similarly in all three epilepsy models.
Next, we searched for any direct and indirect interactions between the 7 genes upregulated in all three epi-
lepsy models or their protein product. Interactions were only observed between Msn and Cd44, whereas other 
genes are not functionally connected (Fig. 3g) suggesting that the genes upregulated are unlikely to underlie one 
metabolic process.
www.nature.com/scientificreports/
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Figure 3. Differentially expressed genes over three models of TLE. (a–c) - Unsupervised hierarchical 
clustering of samples and transcripts according to differential expression profiles (upregulation - red, 
downregulation - blue, cut-off p < 0.001) for the amygdala stimulation (a), TBI (b) and pilocarpine model (c).  
Green bars on the top of the heatmaps refer to control and magenta bars to SE/TBI animals. Data from 
pilocarpine model were previously published by Kobow et al.10 and reanalyzed here as described in Methods 
section. (d) - Heatmap presenting genes with altered expression levels in at least two animal models (cut-off 
p < 0.001). Blue color indicates downregulation and red upregulation of gene expression in a given model of 
epilepsy. The blue bar on the top of the heatmap refers to control and the magenta bar to SE/TBI animals. Black 
shadings on the left side of the heatmap represent the significant differences. (e–f) - Venn diagrams presenting 
upregulated (e) or downregulated (f) genes common between models. (g) - Direct and indirect experimentally 
observed interaction between genes or gene products according to IPA. Note that interactions were found 
between Msn (moesin) and Cd44 (Cd44 antigen precursor), and that feedback interaction was observed for 
www.nature.com/scientificreports/
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We also addressed the question if genes involved in epigenetic regulation of transcription are altered in any 
of studied models. We selected enzymes involved in DNA methylation (DNMTs, TETs), methyl-CpG binding 
domain proteins, histone methyltransferases, demethylases, acetyltransferases, deacetylases, and transcription 
factors having histone modifying properties. At a relaxed cut-off p < 0.01, changes in expression level were found 
for DOT1L (fold change 2.24; p < 0.001), Lysine (K)-Specific Demethylase 6B (KDM6B, fold change 3.302, 
p < 0.01), and PR Domain Containing 2, With ZNF Domain (PRDM2; fold change − 1.26; p < 0.01) in the amyg-
dala stimulation model, and for Enhancer Of Zeste 1 Polycomb Repressive Complex 2 Subunit (EZH1) in the 
pilocarpine model (fold change 1.69, p < 0.01). No changes were observed in genes involved in DNA methylation 
regulation. The increase in the expression of DNMT3A in pilocarpine model (1.64 fold; p = 0.040) did not reach 
our significance criteria.
Functional annotations of genes differentially expressed in each epilepsy model. To determine 
whether genes differentially expressed in each model of epilepsy are a part of a common biological process or 
pathway, we performed enrichment analysis based on annotation terms from GO, KEGG and Reactome (Fig. 3h).
No significantly enriched terms were observed for downregulated genes in the amygdala stimulation and TBI 
models. There were two enriched terms for genes downregulated in the systemic pilocarpine model: synaptic 
transmission and learning or memory (Fig. 3h).
There were 25 enriched terms for upregulated genes in the amygdala stimulation model. The ten most enriched 
terms in order of significance, were as follows: wound healing, negative regulation of molecular function, blood 
coagulation, negative regulation of protein metabolic process, vasculature development, cellular response 
to growth factor stimulus, negative regulation of kinase activity, negative regulation of cell death, response to 
organophosphorus and hemostasis. The enriched terms for upregulated genes in the TBI model were as fol-
lows: immune effector process, innate immune response, negative regulation of multicellular organismal process, 
response to wounding, cell activation, glial cell development, negative regulation of cell differentiation, negative 
regulation of immune effector process, inflammatory response, and interferon alpha/beta signaling. In the sys-
temic pilocarpine model, five enrichment terms characterizing upregulated genes were found: single organism 
cell adhesion, immune effector process, extracellular matrix organization, negative regulation of multicellular 
organismal process, and regulation of cell migration (Fig. 3h). Interestingly, most terms were model-specific 
and only a few occurred in more than one model. Immune effector process was detected in the TBI and systemic 
pilocarpine models, and negative regulation of molecular function was detected in the amygdala stimulation 
and systemic pilocarpine models. Additionally, extracellular organization process, which was the second most 
significantly enriched in the systemic pilocarpine model, was the least significant of all 25 enriched terms in the 
amygdala stimulation model.
These data imply that different biological processes predominate in each chronic epilepsy model, although 
some functional similarities can be observed.
Correlation of aberrant DNA methylation and gene expression in the three epilepsy models. 
To understand the relationships between genomic methylation and gene expression in different models of chronic 
epilepsy in rats, we integrated DNA methylation with gene expression data derived from the same hippocam-
pal specimens. Preliminary analyses of the relationships between methylation changes and mRNA expression 
for systemic pilocarpine model have been previously published10. Here, we extend these results by considering 
methylation events in 3′ UTRs, 5′ UTRs, 5 kb promoter and CGI in the 5 kb promoter. Gene expression profiling 
identified 404 transcripts that were differentially expressed in focal amygdala stimulation, 229 transcripts in TBI, 
and 313 transcripts in pilocarpine models (cut-off p < 0.001).
As shown in Fig. 4a,b in the focal amygdala stimulation model decreased methylation in promoters was linked 
to decreased gene expression. In contrast, the systemic pilocarpine model showed an inverse correlation link-
ing decreased promoter methylation with increased gene expression, whereas no association between decreased 
promoter methylation and gene expression was observed in the TBI model. However, increased methylation of 
promoters in the TBI model was linked to increased gene expression, whereas no such association was detected 
in the other two models. No associations between gene expression and methylation in genomic features, other 
than promoters were detected in the focal amygdala stimulation and TBI models (Fig. 4b). Only in the systemic 
pilocarpine model an association between increased methylation in 3′ UTRs, exons, introns, and 5′ UTRs and 
decreased gene expression was observed as well as between decreased methylation in 3′ UTRs, exons, and introns 
and the increased gene expression, thereby extending previous reports on this data set10.
To further investigate the influence of methylation on gene expression, we concentrated specifically on genes 
that exhibited altered methylation status in at least two models (Fig. 4c). In particular, we investigated promoters 
differentially methylated in all three models. Interestingly, 18 genes had introns that were differentially methyl-
ated in all three epilepsy models. Some common methylation events were observed when comparing epilepsy 
S100a6, Msn and Cd44. (h) - Word clouds presenting enrichment analysis of terms from the GO database 
from the Biological Process branch and terms from biological pathways databases (KEGG and Reactome) 
with gProfiler for each model. The length of blue and red bars over each word cloud are proportional to the 
number of down- and upregulated genes, respectively. The numbers on the right side of the bars (G1 and G2) 
represent the number of down- and upregulated genes, respectively. Word clouds under the blue bars describe 
enriched terms for downregulated genes whereas words under the red bars represent upregulated genes. Only 
significantly enriched terms (enrichment p < 0.01) are presented. The color of the font indicates the enrichment 
p-value. Darker colors indicate more significant enrichment. The font size is related to the significance of 
enrichment of a given term but only within a given cloud.
www.nature.com/scientificreports/
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models in pairs, specifically 15 out of 32 genes with altered methylation in introns common to the focal amygdala 
stimulation model and TBI could be identified. Eleven exhibited increased methylation and four decreased meth-
ylation events (Supplementary Table 3). When comparing focal amygdala stimulation and systemic pilocarpine 
models, 9 methylation events occurred in the same regions in introns. Six exhibited increased methylation and 
three decreased methylation (Supplementary Table 3). Comparisons between TBI and systemic pilocarpine mod-
els revealed 16 common methylation events occurring in the same region in introns. Seven exhibited increased 
methylation and nine decreased methylation (Supplementary Table 3).
To identify individual relationships between DNA methylation changes and gene expression levels in each 
model of epilepsy, we generated a list of differentially expressed genes (cut-off p < 0.001) for which differen-
tially methylated regions of DNA (cut-off p < 0.001) were identified in promoters (defined as 5 kb upstream of 
TSS) or gene bodies. As shown in Fig. 4d, in the focal amygdala stimulation model 8 genes, in which promot-
ers or gene bodies were differentially methylated, were differentially expressed. Changes in promoter methyla-
tion were accompanied by changes in mRNA levels for F1M710_RAT (general transcription factor II-I repeat 
domain-containing protein 1), Jph3 (junctophilin 3), Plk2 (polo-like kinase 2), and Tgfbi (transforming growth 
factor, beta induced). Changes in mRNA expression were accompanied by changes in methylation status in 
introns for Cdh9 (cadherin 9), Dusp4 (dual specificity phosphatase), F1M710_RAT, Nptx2 (neuronal pentraxin 
II), Sipa1|2 (signal-induced proliferation-associated 1 like 2), and Tgfbi. In the TBI model, we identified 3 genes 
Figure 4. Correlation between methylation and gene expression. (a) - Examples of GSEA enrichment 
profiles of association between gene expression and alterations in promoter methylation, A strong association 
(FDR < 0.25 was considered significant) was observed between increased promoter methylation and gene 
activation in the TBI model, between decreased promoter methylation and gene repression in the focal 
amygdala stimulation model, and between decreased promoter methylation and gene activation in the systemic 
pilocarpine model. ES - enrichment score, PRL - pre-ranked list, FDR - false discovery rate. (b) - Gene set 
enrichment analysis (GSEA) presenting associations between gene expression and methylation changes in 
different genomic features in three epilepsy models. The results are presented as false discovery rates of nominal 
p-values of gene sets of increased or decreased methylation events at promotors (5 kb upstream of transcription 
start), CpG islands in promoters (CGI in promoter), TSSs, 3′ UTRs, exons, introns and 5′ UTRs against the rank 
of mRNA-Seq data from the same samples. Cell background color representations are as follows: gray – non-
significant association, green - significant association with decreased gene expression, magenta - significant 
association with increased gene expression (FDR < 0.25 was considered as significant). NA - analysis not 
available due to missing differentially methylated regions in gene sets. (c) - Venn diagrams showing overlaps 
between genes and differentially methylated DNA regions used in GSEA. (d) - List of differentially expressed 
genes (cut-off p < 0.001), in which methylation changes occurred in gene body or promoter regions in each 
model. Magenta and green arrows indicate increased and decreased levels of mRNA, respectively. Orange and 
blue arrows indicate increased and decreased methylation events, respectively, which occurred in promoter 
regions, TSSs, exons, introns, 3′ UTRs, 5′ UTRs and CGIs (CpG islands).
www.nature.com/scientificreports/
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in which changes in mRNA expression were accompanied by changes in methylation in introns Aox1 (aldehyde 
oxidase 1); Clic 1 (chloride intracellular channel 1); Hpcal1 (hippocalcin-like 1)]. In the systemic pilocarpine 
model, changes in the methylation status of introns in Cplx4 (complexin 4), Fam101b (family with sequence 
similarity 101, member B), Grxcr1 (glutaredoxin, cysteine rich 1), Kit (v-kit Hardy-Zukerman 4 feline sarcoma 
viral oncogene homolog), and PNOC_RAT (prepronociceptin) were accompanied by changes of mRNA levels. 
Moreover, changes in the methylation status of Cplx4 were also present in promoter and TSS. No genes with 
altered expression levels and methylation status were common to at least 2 models, indicating model specificity 
in this phenomenon.
Discussion
This study investigated the generality of DNA methylation alterations in three experimental models of chronic 
epilepsy, representing a general pathomechanism regardless of etiology. In all injury models studied, DNA meth-
ylation status clearly distinguished controls from focal amygdala stimulation, systemic pilocarpine and TBI ani-
mals. The models were characterized by markedly increased methylation in gene bodies and hypomethylation in 
non-genic areas. However, analysis of the precise locations of methylation events in the genome did not identify 
regions with altered methylation common to all three models, and only a few regions were common to any two 
models. Modest associations between methylation in different genomic areas and alterations in gene expression 
were observed and appeared to be strongest in the systemic pilocarpine model.
Gene-specific as well as genome-wide alterations in DNA methylation have been previously indicated in epi-
lepsy7,10–15. TLE patients with hippocampal sclerosis and animals with experimental epilepsy have been reported 
with increased DNA methyltransferase (DNMT) levels in the hippocampus12,13,16 and increased global DNA 
methylation12,13. In hippocampus sampled from rat systemic kainate model or patients with drug-refractory 
TLE, there is a clear predominance of increased methylation in gene promoters13,15. Finally, whole-genome 
next-generation sequencing of hippocampal tissue from chronically epileptic animals in the systemic pilocarpine 
model has revealed widespread alterations in methylation status throughout the genome with prevailing hyper-
methylation events in the gene body . Our findings extend these observation by showing that hypermethylation of 
gene bodies is a common feature in experimental models of epilepsy and possibly related to brain hyperexcitabil-
ity. This hypothesis is supported by previous studies demonstrating that therapeutic adenosine augmentation or 
ketogenic diet decrease DNA methylation levels while attenuating epileptogenesis10,13. On the other hand, it has 
been shown that inhibition of DNMT at the time of initial insult in the rat kainic acid model increased excitatory 
postsynaptic potentials in hippocampal slices isolated at 14 d later, and caused a decrease in the latency to the first 
spontaneous seizure12. Moreover increasing DNMT function by methionine supplementation reduced interictal 
spiking in slices from epileptic rats17. Therefore the role of DNA methylation in seizure control is complex and 
may be context-dependent.
Interestingly, comparisons of our datasets with that on promoter methylation in human hippocampal TLE 
samples showed concordance with methylation changes15. For example, in the amygdala stimulation model we 
observe hypermethylation of LLGL2 (lethal giant larvae homolog 2). In the systemic pilocarpine we detected 
hypermethylation of LPHN1, (latrophilin 1) as well as hypomethylation of FER1L4 (fer-1-like 4 pseudogene) in 
TBI. Additionally, hypermethylation in FIGLA (folliculogenesis-specific basic helix-loop-helix) promoter was 
observed in the amygdala stimulation model, and previously, in patients with hippocampal sclerosis. Moreover, 
we found altered methylation in TTLL9 (tubulin tyrosine ligase-like family, member 9) promoter in our TBI 
samples, which has also been observed in patients.
The influence of altered methylation on brain function remains unclear and in the current study gene expres-
sion changes were not inversely correlated with DNA methylation changes, particularly in TBI and focal amyg-
dala stimulation models, which is believed to contribute to gene silencing18. In fact, only a few genes exhibited 
methylation changes in gene promoter with altered in mRNA expression in the focal amygdala stimulation and 
systemic pilocarpine models. We identified genes showing methylation alterations in gene body including exons, 
introns, or on exon-intron junctions independent of gene expression. Recent studies of methylome and transcrip-
tome data also failed to demonstrate clear effect of intragenic methylation on gene expression in different tissues, 
including dorsal root ganglion following peripheral nerve ligation19–21. Infact, these studies show intragenic DNA 
methylation plays a role in exon definition and alternative splicing, as exons with lower methylation levels tend 
to be excluded from mRNA while exons included or highly expressed exhibit higher levels of DNA methyla-
tion20,22,23. Manipulation of the exon methylation affects the inclusion of exons to the nascent mRNA20,24. The 
regulation of splicing mediated by intragenic methylation levels in epileptic animals remains poorly understood.
One interesting finding was the large number of differentially methylated regions located in non-genic 
regions. Similar observations have been made in the brains of schizophrenia or bipolar disorder subjects, as well 
as in experimental model of peripheral pain, indicating the role of intergenic methylation in neurological and 
brain disorders, however the consequences of these changes for genome functioning are not understood21,25.
Interestingly, the alterations in gene expression patterns detected here were primarily model-specific. 
Previously published datasets on different epilepsy models of human tissue also exhibited limited resemblance, 
primarily explained by differences in brain areas, the time points investigated, or the transcriptome profiling 
methods26. Our datasets describing changes in transcriptome in three different models were obtained using the 
same experimental procedure, which indicates that they underlie different model-specific phenomena. Previous 
studies have indicated downregulation of neuron specific gene expression (e.g., synaptic plasticity or learning- 
and memory-related genes) and upregulation of genes involved in different aspects of immune function or 
inflammation26. This is also confirmed here. However, different aspects of the immune response and inflam-
mation predominate in each model. The functional significance of genes that are upregulated in all three mod-
els is unclear, although the importance of complement activation (Serping1), gliosis (S100a6, Msn, Gpnmb), 
or cell-extracellular matrix communication (Cd44) can be implicated. Transcriptome alterations support the 
www.nature.com/scientificreports/
9Scientific RepoRts | 6:25668 | DOI: 10.1038/srep25668
hypothesis that different animal models have distinct characteristics with different predominating molecular 
features.
A surprising finding of this study was the marginal overlap of alterations in DNA methylation between exper-
imental epilepsy models. Because we were interested in methylation patterns identifying epilepsy, we investigated 
models with different epileptogenic etiologies looking for changes that were not related to the model or specific 
laboratory conditions. Rather these changes are indicative of the epileptogenic process and possibly seizures. In 
the focal electrical amygdala stimulation and systemic chemoconvulsant pilocarpine models, epilepsy is sequelae 
of SE27,28. The two models share qualitative similarities in hippocampal pathology, including degeneration of 
interneurons and principal cells, gliosis, axonal sprouting, neurogenesis, and changes in extracellular matrix29 
(see also Fig. 1). At 3 months, when tissue sampling was performed, many of the animals exhibit advanced epi-
leptogenesis, including spontaneous seizures. The variable number of seizures, latency to first seizure and latency 
from last seizure to the tissue collection added to the interindividual variability and may have been a confounding 
factor in our molecular studies. In the TBI model, remarkable interneuron loss in the hippocampus, with milder 
damage to principal cells, gliosis, axonal sprouting, and neurogenesis are observed30(see also Fig. 1). However, 
according to previous studies spontaneous seizures would be expected only in approximately 15% of animals at 
the time point of sampling31,32. In all three models hippocampal pathology is reflected by deficits in hippocampal 
dependent spatial learning, which is most severe in the systemic pilocarpine model27,33,34. Because the structural 
alterations in the CA3 and dentate gyrus are more robust in systemic pilocarpine than in the focal amygdala stim-
ulation or TBI models, at least some differences in the change in methylation status are likely due to differences 
in network change and phenotype. For example, differences in the level of neurodegeneration and accompany-
ing density of glial cell population lead to imbalances between cell types, and because methylation patterns are 
regarded to be cell type-specific, this could explain some differences in methylation alterations between models. 
Additionally, spontaneous seizures being more common in focal amygdala stimulation and systemic pilocarpine 
models could have added to the methylation diversity because persistent epileptiform activity has been shown 
to influence methylation status35,36. However, methylation signatures between the two SE models were not more 
similar than when each of the SE models was compared with the TBI model. We hypothesize the resulting pat-
tern of methylation is dynamic and depends on the stage of the disease development and ongoing pathology. 
Additionally, whether changes in methylation pattern are related to model specific changes in behavior, such as 
stress, mobility or disruption of circadian rhythm, cannot be excluded37,38.
Epilepsy in humans is characterized by extreme heterogeneity both in etiologies and phenotypes that is not 
well modeled by the current animal models and explain the poor reproducibility of preclinical data between 
models and difficulties in translation of potential treatment regimens to the clinical use39. The animal models 
used in this study differ in etiology and may therefore reflect features of different epilepsy syndromes in humans 
(post-traumatic epilepsy vs. drug refractory epilepsy). Our data indicating etiology-related differences in meth-
ylation changes in animal models are in line with human data showing pronounced differences in methylation 
status in epileptic hippocampus depending on the level of hippocampal sclerosis15. Despite the need of integrated 
data analysis between species, comparisons with existing human data sets are currently limited, for example, due 
to the use of different platform technologies (array vs. deep sequencing), limited sample numbers in existing 
studies, lack of human control data, or incomplete annotation of the rat genome.
In summary, we investigated alterations in genomic DNA methylation patterns which were common in three 
different experimental models of acquired epilepsy. Our data revealed that part of the genome-wide methylation 
signature distinguished injured from control animals irrespective of the initial precipitating injury, whereas other 
parts of the signature distinguished epileptic from control animals in a model-specific way. Our data suggest that 
methylation patterns depend on the epileptogenic etiology, indicating either model-specific epileptogenic mech-
anisms or different stages of epileptogenesis at the time of sampling. Future studies are needed to verify the speci-
ficity of our findings and identify molecular biomarkers for epileptogenesis and seizure (onset) or drug-response.
Methods
Epileptogenesis induced by focal electrical amygdala stimulation. Adult male Sprague-Dawley 
rats (Medical Research Centre, Warsaw, Poland) weighing 290–320 g were housed in a controlled environment 
(21–23 °C, 12 h dark/light cycles) with water and food available ad libitum. Starting from the day of surgery, each 
animal was housed in a separate cage. All animal procedures were approved by the Ethical Committee on Animal 
Research of the Nencki Institute and conducted in accordance with the guidelines established by the European 
Council Directives 2010/63/EU. The amygdala stimulation model of temporal lobe epilepsy (TLE) was performed 
as described by Nissinen et al. with modifications27,40. Briefly, surgery was performed under isoflurane anesthe-
sia (2–2.5% in 100% O2) preceded by the injection of butorphanol injection (Butomidor, Richter Pharma AG, 
Wells, Austria; 0.5 mg/kg, i.p.). A stimulating and recording bipolar wire electrode (Plastic One Inc., Roanoke, 
VA, USA, # E363-3-2WT-SPC) were implanted into the left lateral nucleus of the amygdala (AP − 3.6 mm, 
L 5.0 mm from the bregma; DV 6.5 mm from the surface of the brain)41. A stainless steel screw electrode (Plastic 
One Inc., Roanoke, VA, USA, #E363/20) was implanted contralaterally into the skull over the right frontal cortex 
(AP + 3.0 mm, L 2.0 mm from the bregma) as a surface EEG recording electrode. Two stainless steel screw elec-
trodes were placed bilaterally over the cerebellum (AP − 10.0 mm, L 2.0 mm from the bregma) as ground and ref-
erence electrodes. The socket contacts of all electrodes were placed in a multi-channel electrode pedestal (Plastic 
One Inc., Roanoke, VA, USA, #MS363) attached to the skull with dental acrylate (Duracryl Plus). After 2 weeks of 
recovery, animals were electrically stimulated via the intra-amygdala electrode to evoke SE. Stimulation consisted of 
a 100-ms train of 1-ms biphasic square-wave pulses (400 μ A peak to peak) delivered at 60 Hz every 0.5 s for 30 min. 
If the animal did not enter SE, stimulation was continued for an additional 10 min. The SE was stopped 1.5–2 h 
after stimulation via an intraperitoneal injection of diazepam (20 mg/kg; Relanium, Polfa, Warsaw, 5 mg/ml). 
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If the first dose of diazepam did not suppress SE, the animal received subsequent doses of diazepam (5 mg/kg). 
Age-matched control animals had electrodes implanted but did not receive electrical stimulation.
Stimulated rats (n = 5) were monitored with video EEG (Comet EEG, Grass Technologies, West Warwick, 
RI) for 2 weeks prior the end of the experiment to determine the presence of spontaneous seizures. Spontaneous 
seizures were identified from EEG recordings by browsing the EEG manually on the computer screen. An elec-
trographic seizure was defined as a high frequency (>8 Hz), high amplitude (>2 × baseline) discharge lasting 
for at least 5 s. All stimulated animals enrolled had spontaneous seizures. The frequency of seizures was 3.9 ± 2.7 
seizures/day. Time-matched control sham operated animals had electrodes implanted but were not stimulated 
(n = 5).
Epileptogenesis induced by TBI. Adult male Sprague-Dawley rats (Harlan, Netherlands) weighing 
330–371 g at the time of TBI were housed in a controlled environment (21–23 °C, 12 h dark/light cycle, 50–60% 
relative humidity) with water and food available ad libitum. All animal procedures were approved by the 
Committee for the Welfare of Laboratory Animals of the University of Eastern Finland in accordance with the 
guidelines established by the European Community Council Directives 2010/63/UE. The induction of TBI was 
performed according the lateral fluid percussion (LFP) method described by McIntosh et al.42 and Kharatishvili 
et al.31. Animals (n = 18) were anesthetized with an intraperitoneal (i.p.) injection of a solution (6 ml/kg) contain-
ing sodium pentobarbital (58 mg/kg), chloral hydrate (60 mg/kg), magnesium sulphate (127.2 mg/kg), propylene 
glycol (42.8%) and absolute ethanol (11.6%) and placed in a Kopf stereotactic frame (David Kopf Instruments, 
Tujunga, CA, USA). First, the skull was exposed with a midline skin incision followed by extraction of the peri-
osteum. The left temporal muscle was detached from the lateral ridge and then, a circular craniectomy (Ø 5 mm) 
was performed over the left parietal lobe midway between the lambda and bregma keeping the dura mater intact. 
The craniectomy edges were sealed with a modified Luer-Lock cap that was filled with saline, and the calvaria 
was covered with dental acrylate (Selectaplus CN, Dentsply DeTrey GmbH, Dreieich, Germany). Lateral FPI 
was induced 90 min after the administration of anesthesia by connecting the rat to a fluid-percussion device 
(AmScien Instruments, Richmond, VA, USA) via a female Luer-Lock fitting. The mean severity of the impact was 
3.32 ± 0.01 atm. Control animals (n = 12) received anesthesia and underwent all surgical procedures but without 
lateral FPI. Mortality within 48 h post-TBI was 17% (3 of 18 rats). For further analysis, we included 5 TBI and 5 
control rats selected from animals that survived until end of the follow-up period. TBI animals were not subjected 
to EEG-monitoring. They did not express handling-related seizures. Previous data indicate that at this time point 
no more that 15% rats have epilepsy31.
Epileptogenesis induced by systemic pilocarpine. The animal handling procedure and first analysis of 
methylome and transcriptome data obtained from this cohort of rats were previously published by Kobow et al.10. 
Here we reanalyzed and extended the analysis and present new findings when relevant.
Animal procedures have been described elsewhere10. In short, the experimental study design was approved 
by the local animal care and use committee in accordance with the European Communities Council Directive 
(54-2532.1-23/09, Directive 2010/63/EU). Male Wistar rats weighting 300–350 g (Charles-River, Germany; 
n = 14) were kept in individual cages under controlled environmental conditions (12 h dark/light cycles, 20–23 °C 
and 50% relative humidity) with drinking and feeding ad libitum. Representative animals were assigned to con-
tinuous video-electroencephalography monitoring (vEEG; DSI, St. Paul, MN, USA). Electrodes were implanted 
before seizure induction. Rats were deeply anesthetized with an intraperitoneal injection of a ketamine (57 mg/kg) 
and xylazine (9 mg/kg) mixture and placed in a stereotaxic apparatus (Bilaney Consultants, Düsseldorf, 
Germany). Two epidural EEG electrodes, i.e. touching but not penetrating the dura, were implanted (2 mm lateral 
to the sagittal suture and 5 mm anterior to the lambda suture, 1 mm diameter) The transmitter (F40-EET, DSI, St. 
Paul, MN, USA) was placed into a subcutaneous pocket along the animal’s dorsal flank. Implanted animals had 
time to recover for 1 week before further procedures. There were no differences in baseline EEG between animals 
before further treatment.
To induce status epilepticus (SE), animals were injected with a single high dose of the muscarinic receptor 
agonist pilocarpine (PILO; 340 mg/kg, i.p.; Sigma-Aldrich, Steinheim, Germany). Peripheral cholinergic effects 
were minimized by administration of methyl scopolamine (1 mg/kg, s.c.; 30 min before injection of pilocarpine; 
TCI Europe NV, Zwijndrecht, Belgium). Animals that experienced no SE within 45 min after first pilocarpine 
administration were treated for a second time with half the application dosis (175 mg/kg, i.p.). After 60 min SE 
duration, animals received administration of diazepam (8 mg/kg, i.m.; Sigma-Aldrich). One hour following diaz-
epam treatment glucose depots (2 × 5 ml) were subcutaneously injected to help animals to recover. Age matched 
control rats (CTRL; n = 5) received methyl scopolamine and saline (0.9% NaCl; Sigma-Aldrich) injections only.
Implanted animals were video-EEG monitored 24/7 starting from day of implantation until 12 weeks after 
initial precipitating injury. Behavioral seizures were quantified. The average time to first seizure was 8,4 ± 1,8 days 
post-SE. Seizure frequency per week was 24.5 ± 4.7 seizures/week.
Tissue collection. Tissue was collected at 3 months after SE or TBI induction. For tissue collection, the rats 
were anesthetized with CO2 (amygdala stimulation model), 4% isoflurane (TBI), or ether (pilocarpine model), 
and decapitated with a guillotine. The left hippocampus was rapidly isolated, and tissue containing CA3 and 
dentate gyrus were excised on a platform placed on ice. For downstream applications, the CA3/dentate gyrus 
was homogenized in ice cold 1 × PBS and divided into equal volumes for DNA and RNA extraction exactly 
as described by Kobow et al.10. Samples from each animal were processed individually. Samples were stored at 
− 80 °C until use.
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DNA methylation profiling. The same procedure was used for all three models. DNA was extracted from 
a tissue piece containing the CA3 and dentate gyrus using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Massive parallel sequencing of enriched methylated 
DNA was performed as described previously43. Briefly hippocampal DNA from each rat (amygdala stimulation: 
control n = 4, SE n = 4; pilocarpine: control n = 5, SE n = 4; TBI: control n = 4, TBI n = 5) was fragmented to 
a median size of 200–300 bp and subjected to methylated DNA capture according to the MethylMiner proto-
col (Invitrogen, Darmstadt, Germany), exclusively enabling capture of methylated double-stranded DNA. 
Fragmented and enriched DNA was eluted at high salt concentrations (2 M NaCl). Five nanograms of enriched 
DNA for amygdala stimulation, 10 ng for pilocarpine, and 5 ng for TBI was used in library preparation using 
the NEBNext DNA Library Prep Reagent Set for Illumina (New England Biolabs, Frankfurt/Main, Germany). 
The quality of sequencing libraries was assayed using the Shimadzu MultiNA capillary electrophoresis system 
(Shimadzu, Kyoto, Japan). Libraries were sequenced at a concentration of 10 pM using the Illumina Genome 
Analyzer IIx (Illumina, San Diego, CA, USA) with a 36 bp single read length. Image analysis and base-calling were 
performed using the OLBv1.8 software. Sequenced tags were aligned to the rat genome RN4 using BWA (version 
0.5.9) with default parameter44.
Profiles of DNA methylation were compared between all pairwise combinations of samples for each model 
separately using the MACS peak calling software (version 1.4.0 rc2) with fixed shift size of 75 bp and signifi-
cance cut-off of 10E-0545. Genomic regions showing different methylation patterns between pairs of samples were 
merged using BEDTools46. Duplicate reads that aligned to the same location in a given sample were removed from 
further analysis. The number of read tags aligning to each region was summarized using a custom python script 
producing a matrix of counts (tags per region per sample). The regions were non-differentially filtered for regions 
in which the sum of tag counts was below the 50th percentile. These count data were tested for differential tag 
abundance using Bayesian shrinkage of negative binomial model implemented in edgeR47, and normalized using 
trimmed mean normalization48. Circos plot (Fig. 2e) was used to visualize methylation events (cut-off p < 0.01) 
on the rat genome ideogram49. First analyses of alterations in DNA methylation in systemic pilocarpine model 
have been previously published by Kobow et al.10.
Heatmaps were generated in the R environment with the gplots package50,51. Unsupervised clustering was 
performed by taking the trimmed mean normalized values for differential regions as defined by edgeR analysis 
(cut-off p < 0.01). These values were normalized to the standard normal distribution. Methylation events and 
samples were ordered with clustering complete-linkage method together with a Pearson correlation based dis-
tance measure (Fig. 2a–c).
Establishing common differentially methylated regions in the different TLE models. To detect 
of common features in methylation for at least two models, regions with increased or decreased methylation in 
each model (cut-off p < 0.01) were used. To identify common differentially methylated regions between models, 
we used non-adjusted p-values to include regions with low significance; however occurrence in at least two mod-
els was required. Regions, in which alterations in methylation status were common for two or three models were 
detected via intersections with BEDTools v2.16.146. Overlapping regions (≥ 1bp) were considered common when 
the level of methylation between epileptic and control animals changed in the same direction. Circos plot (Fig. 2f) 
was used to map common methylation events to the rat genome ideogram49. Heatmap presenting overlapping 
regions with consistent change (cut-off p < 0.01) in DNA methylation in at least two models of epilepsy (Fig. 2d) 
was generated in the R environment with the gplots package50,51. Unsupervised clustering was performed by tak-
ing the trimmed mean normalized values for differential regions as defined by edgeR analysis for each model of 
epilepsy separately. These values were normalized to the standard normal distribution for each model separately. 
Methylation events and samples were ordered with clustering complete-linkage method together with Pearson 
correlation based distance measure.
Distribution of differentially methylated regions across genomic features. Information about 
genomic features: CpG islands, SNPs, promoters (200 bp or 5 kb upstream of transcription start), TSSs, gene 
bodies, 5′ UTRs, coding exons, introns, 3′ UTRs, and non-genic regions was obtained for rat genome version 
RN4 from Ensembl via the UCSC Genome Table Browser52. We intersected genomic features with differentially 
methylated regions of DNA between epileptic and control animals (cut-off p < 0.01) (overlap 1 bp or more) with 
BEDTools 2.16.146 and compared the distribution of DNA methylation changes for three models for all of these 
genomic features. Differentially methylated regions were normalized and expressed as log2 odds ratio compared 
with non-differentially methylated genomic features separately for hyper- and hypomethylation events. Barplots 
in Fig. 2h–j present the mean frequency of observed methylation changes with upper and lower 95% confidence 
intervals for the genomic features. We also compared hyper- and hypomethylation events at specific genomic 
features for each model. Barplot in Fig. 1k presents log2 odds ratio of the number of increased versus decreased 
methylation regions across genomic features with upper and lower 95% confidence intervals. Significance was 
estimated with two-sided Fisher’s exact test and p < 0.05 was considered significant. Barplots were created, and 
statistical calculations were performed in the R environment version 3.0.250.
Gene expression profiling. The mRNA expression profiling procedure was the same for all three models. 
The numbers of samples analyzed was as follows: amygdala stimulation - control n = 5, SE n = 4; pilocarpine - 
control n = 5, SE n = 5; TBI - control n = 3, TBI n = 5. Total RNA was extracted using the Trizol method, followed 
by DNAse digestion. RNA quality was verified with the Shimadzu MultiNA capillary electrophoresis system 
(Shimadzu). Following Dynabead Oligo(dT) enrichment (Invitrogen), mRNA was prepared into sequence-ready 
libraries with the NEBNext mRNA Library Prep Reagent Set for Illumina (New England Biolabs). Libraries 
were sequenced at a concentration of 10 pM (pilocarpine) or 13 pM (amygdala stimulation and TBI) on the 
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Illumina Genome Analyzer IIx (Illumina, San Diego, CA, USA) with a 36-bp single read length. Image analysis 
and base-calling were performed as described above. Sequenced tags were aligned to the rat genome RN4 using 
BWA (version 0.5.9) with default alignment parameters44. The numbers of read tags aligning to each gene were 
extracted using a custom python script that produces a matrix of counts with regions based on the Ensembl tran-
script annotation (version 66). Genes were non-differentially filtered for tag counts sums below the 30th percen-
tile. These count data were tested for differential tag abundance using Bayesian shrinkage of a negative binomial 
model implemented in edgeR47, and normalized using trimmed mean normalization48.
Heatmaps for individual models were generated in the R environment with gplots package50,51. Unsupervised 
clustering was performed by taking the trimmed mean normalized values for differential genes as defined by 
edgeR analysis (cut-off p < 0.001). These values were normalized to the standard normal distribution. Genes 
and samples were ordered with clustering complete-linkage method together with a Pearson correlation based 
distance measure (Fig. 3a–c) and normalized values. For heatmaps presenting unsupervised clustering of all 
samples and models, z-scores were calculated for each model separately and a Pearson correlation-based distance 
measure was used.
For the seven genes upregulated in all three models of epilepsy we analyzed direct and indirect experimen-
tally confirmed interactions between genes and gene products using IPA (Ingenuity Pathway Analysis, Quiagen, 
Redwood City, CA) (Fig. 3g).
Comparison of functional enrichment of GO terms for the Biological Process branch and biolog-
ical pathways from KEGG and Reactome. Analysis of enriched GO terms from the Biological Process 
branch was performed separately with the gProfiler webservice53,54 via the GOsummaries R package55 for upreg-
ulated and downregulated genes for each epilepsy model (Fig. 3h). Whole genome was used as a reference set. 
The function ‘gosummaries’ from the GOsummaries package was used with default arguments using human GO, 
KEGG and Reactome database as targets.
Gene set enrichment expression analysis. A gene set enrichment analysis (GSEA) was performed 
separately for each model using the ranked mRNA results and sets of differentially methylated genes (cut-off 
p < 0.001)56. Rank scores for differential mRNA expression were calculated as -log10(p-value) multiplied by the 
sign of the edgeR fold change such that upregulated genes had positive scores and downregulated genes had 
negative scores. Scores for genes that were represented by more than one transcript were calculated with the 
lowest p-value. The obtained rank scores were used to test for relationships between gene expression and DNA 
methylation using the GSEA preranked method based on 1000 gene set permutations. Sets of differentially meth-
ylated genes were derived by filtering the differentially methylated regions between epileptic and control animals 
(p < 0.001 as determined by edgeR analysis) and separated into increased and decreased methylation. Promoters 
were defined as regions 5 kb upstream of TSS. An initial analysis of alterations in transcriptome from animals with 
pilocarpine induced epilepsy was previously published by Kobow et al.10.
Differentially expressed genes in which methylation changes occurred. Lists of differentially 
expressed genes (cut-off p < 0.001) were obtained separately for each model of epilepsy. Additionally, a list of 
differentially methylated genes (cut-off p < 0.001), in which methylation changes occurred in gene bodies or 
promoters defined as 5 kb upstream from TSS was obtained. Lists of differentially expressed and methylated genes 
were intersected for each model separately to obtain list of relationships between methylation and expression for 
each animal model presented (Fig. 4d).
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